

[First Hit](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L42: Entry 114 of 127

File: JPAB

Jan 9, 1992

PUB-NO: JP404005231A

DOCUMENT-IDENTIFIER: JP 04005231 A

TITLE: ANALGESIC FOR CHRONIC PAIN

PUBN-DATE: January 9, 1992

INVENTOR-INFORMATION:

NAME

COUNTRY

TAKAGI, HIROSHI

ASSIGNEE-INFORMATION:

NAME

COUNTRY

MORISHITA PHARMACEUT CO LTD

TAKAGI HIROSHI

APPL-NO: JP02106138

APPL-DATE: April 20, 1990

INT-CL (IPC): A61K 31/195



ABSTRACT:

PURPOSE: To provide the title analgesic usable effectively and safely for a long period of time, containing, as active ingredient, L-arginine.

CONSTITUTION: The objective analgesic containing, as active ingredient, L- arginine or its pharmaceutically acceptable salt. The dosage of the L-arginine is 50 - 700 (pref. 100 - 600) mg/kg/day for adult. The present analgesic is effective for herpes occipital pain, various central nervous pains, carcinomatous headache, cluster headache, cervico-brachial syndrome, humeral periarthrititis, spondylosprain, spondylopathy deformans, rheumatic arthrititis, etc.

COPYRIGHT: (C) 1992, JPO&Japio

[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

[All Databases](#)[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[OMIM](#)[PMC](#)[Journals](#)[Books](#)Search 

for

[Limits](#)[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)

Display



Show



Sort by



Send to

[About Entrez](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journals Database](#)[MeSH Database](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[Special Queries](#)[LinkOut](#)[My NCBI](#)[Related Resources](#)[Order Documents](#)[NLM Mobile](#)[NLM Catalog](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)☐ 1: Arthritis Rheum. 1994 Jul;37(7):1062-9.[Related Articles, Links](#)

N-monomethyl arginine, an inhibitor of nitric oxide synthase, suppresses the development of adjuvant arthritis in rats.

Stefanovic-Racic M, Meyers K, Meschter C, Coffey JW, Hoffman RA, Evans CH.

University of Pittsburgh School of Medicine, PA 15261.

OBJECTIVE. To test the hypothesis that nitric oxide (NO) is involved in the pathophysiology of arthritis. **METHODS.** Arthritis was induced in male Lewis rats by the injection of adjuvant into the base of the tail. The NO synthase (NOS) inhibitor, NG-monomethyl-L-arginine (L-NMA), was administered daily by the oral route for 19 days. Paw swelling, plasma fibrinogen levels, and urinary NO₂/NO₃ levels were measured to assess the effect of L-NMA on the arthritic response and whole-body NO production, respectively. On day 20, the ankle joints were processed for histopathologic evaluation. **RESULTS.** The onset of clinical symptoms was preceded by elevated biosynthesis of NO. In a dose-dependent manner, L-NMA inhibited both NO biosynthesis and paw swelling; histopathologic changes in the ankle joints were also prevented. D-NMA had no effect on the development of arthritis, while L-arginine reversed the effects of L-NMA. Fibrinogen levels in rats with arthritis were unaffected by L-NMA. **CONCLUSION.** NO is critical to the development of both the inflammatory and erosive components of adjuvant arthritis in rats. There may be a future clinical role for suitable inhibitors of NO production or activity.

PMID: 7517676 [PubMed - indexed for MEDLINE]

Display



Show



Sort by



Send to

[Write to the Help Desk](#)[NCBI | NLM | NIH](#)[Department of Health & Human Services](#)[Privacy Statement | Freedom of Information Act | Disclaimer](#)

Nov 3 2005 04:38:48

[First Hit](#) [Previous Doc](#) [Next Doc](#) [Go to Doc#](#)

End of Result Set.

☐ [Generate Collection](#) [Print](#)

L96: Entry 131 of 131

File: DWPI

Feb 21, 1974

DERWENT-ACC-NO: 1974-15766V

DERWENT-WEEK: 200402

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Vitamin/hormone ointment - esp for skin disorders

PATENT-ASSIGNEE:

ASSIGNEE

CODE

ALBIN J F

ALBI

PRIORITY-DATA: 1972DE-2240187 (August 16, 1972)

[Search Selected](#)[Search ALL](#)[Clear](#)

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES

MAIN-IPC

[DE 2240187 A](#)

February 21, 1974

000

INT-CL (IPC): A61K 9/06

ABSTRACTED-PUB-NO: DE 2240187A

BASIC-ABSTRACT:

Ointment contains vitamin A (axerophthol) (pref. 0.45 parts), vitamin B6 (pyridoxine hydrochloride) (pref. 0.25 parts), vitamin C (ascorbic acid) (pref. 1.00 part), vitamin D2 (calciferol) (pref. 0.15 parts), vitamin E (tocopheryl acetate) (pref. 0.30 parts), vitamin K 3 (sodium menadione bisulphite) (pref. 0.05 parts), progesterone (pref. 0.05 parts) and testosterone propionate (pref. 0.025 parts per thousand). It is suitable for the treatment of a variety of eye and skin disorders, including conjunctivitis, blepharitis, acne, psoriasis, seborrhoea, ulcer cruris etc., as well as haemorrhoids, fistulae, pruritis ani, anal fissures, phlegmones, gangrene, bruises, myalgias and muscular rheumatism.

TITLE-TERMS: VITAMIN HORMONE OINTMENT SKIN DISORDER

DERWENT-CLASS: B05

CPI-CODES: B01-C04; B01-C05; B03-L; B12-A07; B12-D09; B12-J04; B12-L04; B12-L05;

CHEMICAL-CODES:

Chemical Indexing M1 *01*

Fragmentation Code

Hit List

First Hit

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results - Record(s) 1 through 6 of 6 returned.

- ☐ 1. Document ID: US 20040223984 A1

Using default format because multiple data bases are involved.

L107: Entry 1 of 6

File: PGPB

Nov 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040223984

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040223984 A1

TITLE: Topical testosterone formulations and associated methods

PUBLICATION-DATE: November 11, 2004

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

Kryger, Abraham H.

Monterey

CA

US

US-CL-CURRENT: 424/400; 514/177

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	PubID	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-------	--------

- ☐ 2. Document ID: US 20040220160 A1

L107: Entry 2 of 6

File: PGPB

Nov 4, 2004

PGPUB-DOCUMENT-NUMBER: 20040220160

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040220160 A1

TITLE: Topical testosterone formulations and associated methods

PUBLICATION-DATE: November 4, 2004

INVENTOR-INFORMATION:

NAME

CITY

STATE

COUNTRY

Kryger, Abraham H.

Monterey

CA

US

US-CL-CURRENT: 514/177; 514/458

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	PubID	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-------	--------

☐ 3. Document ID: US 20040220154 A1

L107: Entry 3 of 6

File: PGPB

Nov 4, 2004

PGPUB-DOCUMENT-NUMBER: 20040220154

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040220154 A1

TITLE: Topical testosterone formulations and associated methods

16/765003

PUBLICATION-DATE: November 4, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kryger, Abraham H.	Monterey	CA	US

US-CL-CURRENT: 514/171; 514/458

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Draw
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------

☐ 4. Document ID: US 20020150625 A1

L107: Entry 4 of 6

File: PGPB

Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020150625

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020150625 A1

TITLE: Topical testosterone formulations and associated methods

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kryger, Abraham H.	Monterey	CA	US

US-CL-CURRENT: 424/489; 514/171, 514/458, 514/565

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Draw
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------

☐ 5. Document ID: US 6743448 B2

L107: Entry 5 of 6

File: USPT

NO. Jun 1, 2004

US-PAT-NO: 6743448

DOCUMENT-IDENTIFIER: US 6743448 B2

TITLE: Topical testosterone formulations and associated methods

DATE-ISSUED: June 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kryger; Abraham H.	Monterey	CA	93940	

US-CL-CURRENT: [424/489](#); [424/484](#), [424/486](#), [424/501](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Index	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-------	----------

☐ 6. Document ID: WO 2055020 A2

L107: Entry 6 of 6

File: EPAB

Jul 18, 2002

PUB-NO: WO002055020A2

DOCUMENT-IDENTIFIER: WO 2055020 A2

TITLE: TOPICAL TESTOSTERONE FORMULATIONS AND ASSOCIATED METHODS

PUBN-DATE: July 18, 2002

INVENTOR-INFORMATION:

NAME	COUNTRY
KRYGER, ABRAHAM	

INT-CL (IPC): [A61 K 0/](#)EUR-CL (EPC): [A61K009/06](#); [A61K031/195](#), [A61K031/198](#) , [A61K031/355](#) , [A61K031/56](#) ,
[A61K031/568](#) , [A61K047/10](#) , [A61K047/14](#) , [A61K047/18](#) , [A61K047/34](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Index	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-------	----------

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)



Terms

Documents

L106 near2 abraham

6

Display Format: [Change Format](#)[Previous Page](#)[Next Page](#)[Go to Doc#](#)



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals E

Search PubMed ☐ for

Limits Preview/Index History Clipboard Details

Display Abstract ☐ Show 20 ☐ Sort by ☐ Send to ☐

About Entrez

All: 1 Review: 0 ☐

Text Version

☐ 1: Ann Rheum Dis. 1996 Nov;55(11):811-5. Related Articles, Links

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

Androgens as adjuvant treatment in postmenopausal female patients with rheumatoid arthritis.

Booji A, Biewenga-Booji CM, Huber-Bruning O, Cornelis C, Jacobs JW, Bijlsma JW.

Department of Rheumatology and Clinical Immunology,
University Hospital Utrecht, The Netherlands.

OBJECTIVE: To examine the possible beneficial effect of androgens in postmenopausal women with active rheumatoid arthritis. **METHODS:** 107 women participated in a double blind placebo controlled trial to evaluate the effect of 50 mg testosterone propionate intramuscularly every two weeks for one year. **RESULTS:** An improvement in ESR, Dutch health assessment questionnaire, and pain was noted. In addition, 21% of patients treated with testosterone fulfilled the ACR improvement criteria after one year, versus only 4% of the placebo group. The treatment was well tolerated. **CONCLUSIONS:** Testosterone may improve the general wellbeing of postmenopausal women with active rheumatoid arthritis.

Publication Types:

- Clinical Trial
- Randomized Controlled Trial